# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3838089

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

## **CONVEYING PARTY DATA**

Name	Execution Date
JINGCHUN YAO	04/19/2016
XIN LI	04/19/2016
YONGXIA GUAN	04/19/2016
GUANGYAN LI	04/19/2016

# **RECEIVING PARTY DATA**

Name:	LUNAN PHARMACEUTICAL GROUP CORPORATION	
Street Address:	NO. 209, HONGQI ROAD	
City:	LINYI CITY, SHANDONG PROVINCE	
State/Country:	CHINA	
Postal Code:	276006	

## **PROPERTY NUMBERS Total: 1**

Property Type	Number
PCT Number:	CN2014088944

# **CORRESPONDENCE DATA**

Fax Number: (216)621-6165

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 216-621-1113

Email: dbachtel@rennerotto.com **Correspondent Name:** HEIDI A. BOEHLEFELD Address Line 1: **1621 EUCLID AVENUE** Address Line 2: NINETEENTH FLOOR Address Line 4: CLEVELAND, OHIO 44115

ATTORNEY DOCKET NUMBER:	LUNGP0155WOUS	
NAME OF SUBMITTER:	HEIDI A. BOEHLEFELD	
SIGNATURE:	/Heidi A. Boehlefeld/	
DATE SIGNED:	04/20/2016	
	This document serves as an Oath/Declaration (37 CFR 1.63).	

**Total Attachments: 3** 

**PATENT** REEL: 038331 FRAME: 0384

503791442

source=LUNGP0155WOUS\_Assignment\_filed\_04202016#page1.tif source=LUNGP0155WOUS\_Assignment\_filed\_04202016#page2.tif source=LUNGP0155WOUS\_Assignment\_filed\_04202016#page3.tif

> PATENT REEL: 038331 FRAME: 0385

# COMBINED DECLARATION AND ASSIGNMENT (US RIGHTS ONLY) FOR UTILITY OR DESIGN PATENT APPLICATION

Title of Invention: USE OF ICARITIN IN PREPARING MEDICAMENT FOR PREVENTING TREATING HEMATOCYTOPENIA	G OR

As a below named inventor, I hereby declare that this declaration and assignment are directed to:

Application No. (Express Mail Label No.)	PCT/CN2014/088944	
Filing Date (Deposit Date)	20 October 2014	
Amended on (if applicable)		

or, if no application is identified above, the attached application.

#### **DECLARATION**

The above application was made or authorized to be made by me.

I believe that I am the original or an original joint inventor of a claimed invention in the application.

My residence, mailing address and citizenship are as stated below next to my name.

I have reviewed and understand the contents of the application, including the claims.

I hereby acknowledge that any willful false statement made in this declaration is punishable under Section 1001 of Title 18 of the United States Code by fine or imprisonment of not more than five (5) years, or both.

## FOREIGN PRIORITY CLAIM

I hereby claim, on my behalf or on behalf of the below-identified Assignee(s), priority benefits under 35 U.S.C. § 119 (a)-(d) or (f), § 172 or § 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or § 365(a) of any PCT international application(s) which designated at least one country other than the United States of America, that is/are listed below, and have also identified below any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s) or any PCT international application(s) having a filing date before that of the application(s) on which priority is claimed.

COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY NOT CLAIMED
CN	201310493718.4	21 October 2013	
CN	201310646101.1	04 December 2013	

# CLAIM FOR BENEFIT OF EARLIER U.S. PROVISIONAL APPLICATION(S) UNDER 35 U.S.C. § 119(e)

I hereby claim, on my behalf or on behalf of the below-identified Assignee(s), the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) that is/are listed below.

U.S. PROVISIONAL APPLICATION NUMBER	DATE OF FILING (day, month, year)

# DOMESTIC PRIORITY CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S) UNDER 35 U.S.C. § 120

I hereby claim, on my behalf or on behalf of the below-identified Assignee(s), the benefit under 35 U.S.C. § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is

• 1 of 3 PA

PATENT REEL: 038331 FRAME: 0386 not disclosed in that/those prior application(s) in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. APPLICATION NUMBER	DATE OF FILING (day, month, year)	PATENT NUMBER

#### **DUTY OF DISCLOSURE**

I hereby acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. § 1.56, which in pertinent part states that information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and (1) it establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or (2) it refutes, or is inconsistent with, a position the applicant takes in: (i) opposing an argument of unpatentability relied on by the Office, or (ii) asserting an argument of patentability. A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

#### **ASSIGNMENT**

For good and valuable consideration, receipt of which is hereby acknowledged, I have sold and assigned and hereby sell and assign to:

Assignee(s)	Address
Lunan Pharmaceutical Group Corporation	No. 209, Hongqi Road, Linyi City, Shandong Province, 276006 China

[If more than one assignee is listed, each owns an undivided equal share in the application and underlying invention so far as concerns the United States unless otherwise indicated or agreed to by the assignees.]

and the successors and assigns thereof, the entire right, title and interest to said invention so far as concerns the United States and the Territories and Possessions thereof, including the right to claim priority, and said application and all Letters Patent of the United States to be obtained on said application, and any related applications including any nonprovisional application, continuation, division, renewal, substitute or reissue thereof, for the full term or terms for which the same may be granted, and any U.S. nonprovisional, U.S provisional and/or U.S. national phase patent application on which priority is claimed.

If the application number and filing date are not set forth above, authorization is hereby given for any attorney of record in the subject patent application to insert below the application number and filing date information for this application when that information becomes available.

Application No.	PCT/CN2014/088944
Filing Date	20 October 2014

I hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into that would conflict with this assignment and sale.

I further covenant that Assignee(s) will, upon request, be provided promptly with all pertinent facts and documents relating to said application, said invention and said Letters Patent as may be known and accessible to me and will testify as to the same in any proceeding related thereto and will promptly execute and deliver to Assignee(s), or the legal representative thereof, any and all papers, instruments or affidavits required to apply for, obtain, maintain and enforce said application, said invention and said Letters Patent which may be necessary or desirable to carry out the purposes hereof.

Page 2 of 3

PATENT REEL: 038331 FRAME: 0387 I agree that this assignment shall be construed in accordance with the law of the appropriate jurisdiction within the United States, and without regard to its conflicts of laws provisions.

Legal Name of inventor:			Zhiquan ZHAO		
Inventor's signature:				Date:	
			yi City, Shandong Province, P. R. China		
Post Office Address:			armaceutical Group Corporation , No. 209 ovince, 276006 P. R. China	9, Hongqi I	Road, Linyi City,
Logal Name of in	entor		Jingchun YAO		
Legal Name of Inventor:			angenun 170		
Inventor's signature:	the de	春		Date:	2016.04.19
Residence: (City & Stat	Linyi City, Shandong Province, P. R. China				
Post Office Address:	c/o Lunan Pharmaceutical Group Corporation , No. 209, Hongqi Road, Linyi City, Shandong Province, 276006 P. R. China				
Legal Name of Inv	entor:		Xin LI	<b>,</b>	
Inventor's signature:	多欣			Date:	2016.04.19
Residence: (City & Stat			yi City, Shandong Province, P. R. China		
Post Office Address:			armaceutical Group Corporation , No. 20 ovince, 276006 P. R. China	9, Hongqi	Road, Linyi City,
Legal Name of Inventor:			Yongxia GUAN		
Inventor's signature:	美彩	馥		Date:	2016.04:19
Residence: (City & Stat	te/Country):	Lin	yi City, Shandong Province, P. R. China	Citizenship	: CN
Post Office Address:			armaceutical Group Corporation , No. 20 ovince, 276006 P. R. China	9, Hongqi	Road, Linyi City,
Legal Name of Inventor:			Guangyan LI		
Inventor's signature:	李光艳		<b>り</b>	Date:	W16.04,19
, ,			yi City, Shandong Province, P. R. China	Citizenship	
Post Office Address:	c/o Lunan Pharmaceutical Group Corporation , No. 209, Hongqi Road, Linyi City, Shandong Province, 276006 P. R. China				

Page 3 of 3

PATENT REEL: 038331 FRAME: 0388

**RECORDED: 04/20/2016**